Many people taking Wegovy experience gastrointestinal side effects, including nausea, indigestion, and acid reflux, particularly during initial treatment or dose increases
Currently, once-weekly subcutaneous semaglutide 2.4 mg is approved for chronic weight management in adults with obesity, or overweight and with at least one weight-related comorbidity 17 , for reducing CV risk in adults with established cardiovascular disease (CVD) with obesity or overweight 18 , and in adolescents aged 12 years and older 19 , in conjunction with a reduced-calorie diet and increased physical activity plan
5 SNAC works by temporarily raising the pH around the tablet in the stomach, thereby protecting semaglutide from acid degradation
Cuando la semaglutida no funciona para bajar de peso, mltiples factores pueden estar involucrados: desde adherencia inadecuada y efectos adversos hasta condiciones metablicas subyacentes y medicamentos concomitantes
Schedule a consultation today to explore the benefits of weight loss management